Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ST-100
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : AJU Pharm
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Stuart Therapeutics, Inc. announces licensing agreement with Aju Pharm Co. Ltd.
Details : ST-100 is part of Stuart's PolyCol™ (PolyCol) platform of synthesized collagen mimetics, which target and treat disease damaged extracellular matrix (ECM) collagen.
Brand Name : ST-100
Molecule Type : Peptide
Upfront Cash : Undisclosed
January 03, 2023
Lead Product(s) : ST-100
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : AJU Pharm
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?